Medicinal chemistry – Page 61
-
News
Tufts’ $2.6bn drug development figure questioned
Details sought about how university determined cost of bringing a drug to market jumped 145% since 2003
-
PodcastCannabicyclohexanol
Used to make synthetic cannabis, cannabicyclohexanol may be more risky than its non-synthetic counterpart
-
NewsEbola vaccine passes first safety hurdle
Researchers hope to begin larger trials of its effectiveness in west Africa soon
-
OpinionProgress at the pace of the slowest
Chemistry is rarely the rate-limiting process in getting a drug to market, says Derek Lowe
-
-
News
US drug development costs surge
The price of developing new prescription drugs in the US has increased 145% since 2003, Tufts data shows
-
-
News
Mouse model to assess chemical exposure
Outbred mice can be used predict how human’s will respond to harmful chemicals with examination of chromosomal damage
-
Research
Aptamers and gold nanoparticles whisked up to spot influenza
Gold-coated flu viruses sink in visual bioassay
-
Business
Labcorp to buy Covance and enter contract research
Firm wants to diversify away from diagnostics, but law firm investigation suggests investors are unconvinced of the deal’s value
-
PodcastPsilocybin & Mescaline
Simon Cotton explores our hallucinogenic horizons with psilocybin and mescaline
-
ResearchSleeping sickness fly trap in a nutshell
Isomerising-cross metathesis could help curb tropical disease by converting cashew byproduct into sustainable pest control
-
PodcastChemistry World podcast - November 2014
We speak to Eric Betzig about his Nobel prize-winning research, and find out how thermoelectric materials can be made more efficient
-
ResearchReview finds nanosafety is no small issue
Audit of safety studies reveals shortcomings that distort our understanding of nanomaterial toxicity
-
NewsUS agency fast-tracks Ebola vaccine development
Health and Human Services invests almost $6 million to ready an Ebola vaccine candidate for clinical trials, meanwhile GSK says its vaccine is progressing at an ‘unprecedented rate’
-
NewsEuropean commission looks for endocrine disruptor definition
Consultation seeks opinion on a scientific description for these chemicals to help inform existing regulation
-
-
News
US ramps up rare diseases research
National Institutes of Health spends $29 million to study more than 200 rare diseases
-
-
Business
Actavis boosts antibiotics with Durata buyout
$820 million deal gives Actavis control of newly-approved intravenous antibiotic